ALEXION PHARMACEUTICALS, INC. - FORM 10-K - EX-32.1 - CERTIFICATION OF CEO PURSUANT TO SECTION 906 - February 8, 2018

Attached files

file filename
EX-32.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 906 - ALEXION PHARMACEUTICALS, INC.alxnex32212312017.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 302 - ALEXION PHARMACEUTICALS, INC.alxnex31212312017.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO SECTION 302 - ALEXION PHARMACEUTICALS, INC.alxnex31112312017.htm
EX-23.1 - CONSENT OF PRICEWATERHOUSECOOPERS LLP - ALEXION PHARMACEUTICALS, INC.alxnex23112312017.htm
EX-21.1 - SUBSIDIARIES OF ALEXION PHARMACEUTICALS, INC. - ALEXION PHARMACEUTICALS, INC.alxnex21112312017.htm
EX-10.39 - FORM OF 2017 INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT FOR NON-US PARTICIPA - ALEXION PHARMACEUTICALS, INC.alxnex103912312017.htm
EX-10.38 - FORM OF 2017 INCENTIVE PLAN GLOBAL STOCK OPTION AGREEMENT - ALEXION PHARMACEUTICALS, INC.alxnex103812312017.htm
EX-10.37 - FORM OF 2017 INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT FOR FRENCH PARTICIPA - ALEXION PHARMACEUTICALS, INC.alxnex103712312017.htm
EX-10.36 - 2017 INCENTIVE PLAN RULES FOR AWARDS GRANTED TO PARTICIPANTS IN FRANCE - ALEXION PHARMACEUTICALS, INC.alxnex103612312017.htm
EX-10.35 - FORM OF 2017 INCENTIVE PLAN PERFORMANCE STOCK UNIT AGREEMENT (R&D UNITS) - ALEXION PHARMACEUTICALS, INC.alxnex103512312017.htm
EX-10.34 - FORM OF 2017 INCENTIVE PLAN PERFORMANCE STOCK UNIT AGREEMENT (TSR) - ALEXION PHARMACEUTICALS, INC.alxnex103412312017.htm
EX-10.33 - FORM OF 2017 INCENTIVE PLAN NONQUALIFIED STOCK OPTION AGREEMENT - ALEXION PHARMACEUTICALS, INC.alxnex103312312017.htm
EX-10.32 - FORM OF 2017 INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT - ALEXION PHARMACEUTICALS, INC.alxnex103212312017.htm
EX-10.6 - EMPLOYMENT AGREEMENT - ALEXION PHARMACEUTICALS, INC.alxnex10612312017.htm
10-K - FORM 10-K - ALEXION PHARMACEUTICALS, INC.alxn10k12312017.htm


Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Alexion Pharmaceuticals, Inc. (the “Company”) for the year ended December 31, 2017 as filed with the Securities and Exchange Commission (the “Report”), I, Ludwig N. Hantson, Ph.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Dated:
February 8, 2018
 
/s/    LUDWIG N. HANTSON, Ph.D.
 
 
 
Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



ALEXION PHARMACEUTICALS, INC. Reports